SPIA
PVLA

Steward Partners Investment Advisory’s Palvella Therapeutics PVLA Stock Holding History

Steward Partners Investment Advisory’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06K Hold
20
– – ﹤0.01% 4129
2026
Q1 		$2.49K Hold
20
– – ﹤0.01% 3994
2025
Q4 		$2.09K Hold
20
– – ﹤0.01% 3947
2025
Q3 		$1.25K Buy
+20
New +$892 ﹤0.01% 4021

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Steward Partners Investment Advisory's PVLA Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 20 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

Steward Partners Investment Advisory first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 181 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Steward Partners Investment Advisory held 20 shares of Palvella Therapeutics worth $3.06K as of Q2 2026.
  • Steward Partners Investment Advisory left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4129 holding.
  • Steward Partners Investment Advisory first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 181 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.